Wednesday, March 24, 2021

2021 SGO Virtual Meeting Sunday March 21, 2021

I am happy to share with you Tweets that cover the work presented during the last full day session of SGO was on Sunday, March 21, 2021.

One session, Time to Return to the Drawing Board, reported clinical trial results that did not meet their aims. Understanding where a drug or treatment may have failed to provide the results expected is as important as those trials that meet aims.




Durvalumab and Trememlimumab

Additional sessions of interest.

Barriers to Quality of Care - Poster 

Uterine lavage and early detection

Post operative opiods use model 

Neuropathy and genetic variants 

Gross resection and OS / NACT

Vulvar Cancer Studies 

Endometrial cancer 

Cediranib and Olaparib NRG GY012



Here are some articles from various sources that go more into depth about studies discussed at the meeting. 

Medscape article on hormone IUD and endometrial cancer

Vulvar cancer patients with sentinel node micrometastases, radiation therapy (RT) to the groin after local excision led to extremely low rates of recurrence, a phase II trial suggested 

ABV-500 small molecule in OC


Thank you so Eisai for supporting patient advocates at the annual meeting . 

Thank you SGO leadership for making us feel welcome and for all the gyn oncs who answered our questions.  


Every Day is a Blessing!

Tuesday, March 23, 2021

2021 SGO Virtual Annual Meeting Saturday March 20

Here are highlights from the Virtual #SGOmtg sessions I attended on Saturday March 20, 2021. 

The morning began with a wonderful get-together for Patient Advocates at a 9am session. I am so glad to see patient advocates play a role in so many aspects of the SGO organization.

 In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags


MEDSCAPE shared this article on MIS and interval debulking surgery.


PAOLA-1 Olaparib plus Bev

Tumor infiltrating lymphocytes

Keynote 158 Cervical Cancer


 ENGOT-OV 16/ NOVA  niraparib

PARP Inhibitor duration of follow-up

Cervical Cancer Radiation study

Shared Decision Making Tool

Niraparib as Maintenance Therapy- Dr Matalunis

Stop by tomorrow for my Sunday highlights.  


Every Day is a Blessing!

Monday, March 22, 2021

2021 SGO Virtual Annual Meeting - Friday March 19th Highlights

I was happy to be able to attend the virtual SGO Annual Meeting. The meeting started on Friday, March 19 with sessions during the day and evenings over the weekend. The meeting continues with evening sessions through Thursday March 25th.  Interacting with presenters and others in the chat feature of the meeting platform was exceptionally good and helpful.

 In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags. Below are some tweets of Fridays sessions I found most interesting.


Nutritional Supplements 

Patient physician conversations

 PARP  inhibitors 


ARIEL 4  Rucaparib vs chemo

KEYNOTE 146  Pembrolizumab - Lenvatinib

Additional information may be found in the ASCO Post Article

Secondary Cytoreductive Surgery

Endometrial Cancer

Equity in Gyn Cancers

ACA and insurance

Here was a fun activity on the meeting platform - puzzle time! How I wish we were actually in Seattle





Every Day is a Blessing!